Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Agnes Ang

1PUBLICATIONS

10CO-AUTHORS

Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Nov 09, 2022

Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in <i>RAS/RAF</i> Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy.

Christine M Parseghian, Ryan Sun, Melanie Woods

Pageof 1

Frequent Collaborators

1 joint publications

Christine M Parseghian

1 joint publications

Hey Min Lee

1 joint publications

Jason Willis

1 joint publications

Shakayla Nunez

1 joint publications

Kanwal P Raghav

1 joint publications

Van K Morris

1 joint publications

John P Shen

1 joint publications

Eduardo Vilar

1 joint publications

Teresa Troiani

1 joint publications

Scott Kopetz

Frequent Collaborators

1 joint publications

Christine M Parseghian

1 joint publications

Hey Min Lee

1 joint publications

Jason Willis

1 joint publications

Shakayla Nunez

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos